Shares of MannKind Corporation (NASDAQ: MNKD), a commercial-stage biopharma focused primarily on inhaled insulin, were up as much as 12% in afternoon trading on Tuesday. Shares had risen about 9% as of 3:45 p.m. EST.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,